Relationship between Resistin, Endothelin-1, and Flow-Mediated Dilation in Patient with and without Metabolic Syndrome.
Endothelin-1
flow-mediated dilation
metabolic syndrome
resistin
Journal
Advanced biomedical research
ISSN: 2277-9175
Titre abrégé: Adv Biomed Res
Pays: India
ID NLM: 101586897
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
18
4
2019
pubmed:
18
4
2019
medline:
18
4
2019
Statut:
epublish
Résumé
Resistin is peptides that signal the functional status of adipose tissue to the brain and other target organs. It causes insulin resistance and affects the vascular endothelial dysfunction. However, the function and relation between resistin in endothelin-1 (ET-1), which leads to the endothelial dysfunction in humans are enigmatic. In a cross-sectional study of 76 participants (38 metabolic syndrome patients and 38 healthy participants), biochemical and clinical parameters, including lipid profile, fasting glucose, resistin, ET-1, C-reactive protein (CRP), flow-mediated dilation (FMD), and hypertension were determined and compared between the two groups. Multiple linear regression analysis was performed with age- and sex-adjusted plasma resistin levels, FMD, and ET-1 as the dependent variables. Analysis showed that weight, body mass index, triglycerides (TGs), and ET-1 were statistically significant correlated with serum resistin. FMD has negative significantly correlated with weight ( In this study, results shown plasma ET-1 and resistin are suggested as risk factors for the development of endothelial dysfunction and with further study, it is possible that can diagnose the risk of diabetes and cardiovascular disease in the early stages.
Sections du résumé
BACKGROUND
BACKGROUND
Resistin is peptides that signal the functional status of adipose tissue to the brain and other target organs. It causes insulin resistance and affects the vascular endothelial dysfunction. However, the function and relation between resistin in endothelin-1 (ET-1), which leads to the endothelial dysfunction in humans are enigmatic.
MATERIALS AND METHODS
METHODS
In a cross-sectional study of 76 participants (38 metabolic syndrome patients and 38 healthy participants), biochemical and clinical parameters, including lipid profile, fasting glucose, resistin, ET-1, C-reactive protein (CRP), flow-mediated dilation (FMD), and hypertension were determined and compared between the two groups.
RESULTS
RESULTS
Multiple linear regression analysis was performed with age- and sex-adjusted plasma resistin levels, FMD, and ET-1 as the dependent variables. Analysis showed that weight, body mass index, triglycerides (TGs), and ET-1 were statistically significant correlated with serum resistin. FMD has negative significantly correlated with weight (
CONCLUSION
CONCLUSIONS
In this study, results shown plasma ET-1 and resistin are suggested as risk factors for the development of endothelial dysfunction and with further study, it is possible that can diagnose the risk of diabetes and cardiovascular disease in the early stages.
Identifiants
pubmed: 30993086
doi: 10.4103/abr.abr_126_18
pii: ABR-8-16
pmc: PMC6425749
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Annu Rev Physiol. 1999;61:391-415
pubmed: 10099694
Am J Cardiol. 2000 Feb 1;85(3):381-5
pubmed: 11078311
Nature. 2001 Jan 18;409(6818):307-12
pubmed: 11201732
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Lancet. 2002 Jan 5;359(9300):46-7
pubmed: 11809189
Eur J Endocrinol. 2002 Nov;147(5):571-4
pubmed: 12444887
Biochem Biophys Res Commun. 2003 Jan 10;300(2):472-6
pubmed: 12504108
Biochem Biophys Res Commun. 2003 Jan 17;300(3):674-8
pubmed: 12507502
Zhonghua Yi Xue Za Zhi. 2002 Dec 10;82(23):1609-12
pubmed: 12667367
Can J Physiol Pharmacol. 2003 Jun;81(6):533-41
pubmed: 12839265
Am J Physiol Heart Circ Physiol. 2004 Nov;287(5):H2043-8
pubmed: 15059773
J Renin Angiotensin Aldosterone Syst. 2004 Sep;5(3):109-13
pubmed: 15526245
Circulation. 2005 Feb 22;111(7):932-9
pubmed: 15710760
Metabolism. 2005 Apr;54(4):471-5
pubmed: 15798953
Lancet. 2005 Apr 16-22;365(9468):1415-28
pubmed: 15836891
Eur Rev Med Pharmacol Sci. 2005 May-Jun;9(3):161-5
pubmed: 16080635
Diabetologia. 2005 Nov;48(11):2330-3
pubmed: 16143861
J Clin Endocrinol Metab. 2006 Jul;91(7):2755-60
pubmed: 16608899
Eur J Endocrinol. 2007 Feb;156(2):279-84
pubmed: 17287419
Diabetes Care. 2007 Jun;30(6):1501-6
pubmed: 17384338
Chin Med J (Engl). 2007 May 20;120(10):871-5
pubmed: 17543176
Int J Cardiol. 2008 Jul 21;127(3):337-41
pubmed: 17659795
Horm Metab Res. 2007 Oct;39(10):710-6
pubmed: 17952831
Curr Diabetes Rev. 2005 Aug;1(3):227-34
pubmed: 18220599
J Am Coll Cardiol. 2008 Mar 11;51(10):997-1002
pubmed: 18325438
Int J Cardiol. 2009 Jun 12;135(1):130-1
pubmed: 18495275
Diabetes Care. 2009 Feb;32(2):329-34
pubmed: 18957529
JPEN J Parenter Enteral Nutr. 2008 Nov-Dec;32(6):638-44
pubmed: 18974244
Diabetologia. 2010 Feb;53(2):234-46
pubmed: 19727657
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H193-201
pubmed: 20435848
J Atheroscler Thromb. 2011;18(2):108-14
pubmed: 21071880
Front Biosci (Landmark Ed). 2011 Jan 01;16:1663-74
pubmed: 21196255
Horm Metab Res. 2011 Mar;43(3):205-8
pubmed: 21264799
Am J Physiol Heart Circ Physiol. 2011 Sep;301(3):H689-95
pubmed: 21666117
Circulation. 1990 Jul;82(1):188-95
pubmed: 2194695
Free Radic Biol Med. 2012 Jan 1;52(1):70-9
pubmed: 22001745
Free Radic Biol Med. 2012 Jan 1;52(1):95-102
pubmed: 22019438
Pak J Pharm Sci. 2012 Jan;25(1):123-9
pubmed: 22186319
Expert Rev Cardiovasc Ther. 2012 Jul;10(7):933-9
pubmed: 22908926
Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1401-8
pubmed: 23520168
Obes Facts. 2013;6(4):393-404
pubmed: 23970148
Hypertension. 2014 Feb;63(2):376-82
pubmed: 24277765
Horm Metab Res. 2014 Jun;46(7):493-8
pubmed: 24627104
Metabolism. 2014 Jul;63(7):951-6
pubmed: 24856242
Diabetes Metab Syndr. 2015 Oct-Dec;9(4):266-70
pubmed: 25311818
Vital Health Stat 3. 2016 Aug;(39):1-46
pubmed: 28437242
Horm Metab Res. 2018 Jul;50(7):521-536
pubmed: 29991083